Abstract
Systemic inflammation score (SIS) is one of the prognostic indicators using lymphocyte-to-monocyte ratio (LMR) and serum Alb level, and has been reported in various solid tumors recently. However, its significance in patients treated with chemoradiotherapy (CRT) for esophageal squamous cell carcinoma (ESCC) remains unclear. The aim of the present study is to investigate the clinical usefulness of SIS in patients who underwent CRT for ESCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
